ES2188596T3 - Moduladores alostericos del receptor nmda. - Google Patents

Moduladores alostericos del receptor nmda.

Info

Publication number
ES2188596T3
ES2188596T3 ES93923173T ES93923173T ES2188596T3 ES 2188596 T3 ES2188596 T3 ES 2188596T3 ES 93923173 T ES93923173 T ES 93923173T ES 93923173 T ES93923173 T ES 93923173T ES 2188596 T3 ES2188596 T3 ES 2188596T3
Authority
ES
Spain
Prior art keywords
submission
activation
nmda receptor
new class
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93923173T
Other languages
English (en)
Inventor
Maria-Luisa Maccecchini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2188596T3 publication Critical patent/ES2188596T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

SE DESCRIBE UNA NUEVA CLASE DE COMPUESTOS PARA LA FABRICACION DE UN MEDICAMENTO PARA: 1) TRATAR TRASTORNOS NEUROLOGICOS, NEUROPSICOLOGICOS, NEUROPSIQUIATRICOS, NEURODEGENERATIVOS, NEUROPSICOFARMACOLOGICOS Y FUNCIONALES, RELACIONADOS CON ACTIVACION EXCESIVA O INSUFICIENTE DEL SUBTIPO DE GLUTAMATO DEL RECEPTOR DE NMDA; 2) TRATAR TRASTORNOS COGNOSCITIVOS RELACIONADOS CON ACTIVACION O DESACTIVACION SUBOPTIMA DEL SUBTIPO DE GLUTAMATO DEL RECEPTOR DE NMDA; Y 3) MEJORAR Y REFORZAR LOS PROCESOS DE MEMORIA, APRENDIZAJE Y MENTALES ASOCIADOS. LOS COMPUESTOS DE LA NUEVA CLASE, DERIVADOS DE LA TOXINA COPNANOTOQUINA-C, ACTUAN COMO MODULADORES ALOSTERICOS DEL CANAL DE CATIONES DEL RECEPTOR NMDA, Y TIENEN EFECTOS QUE OSCILAN DESDE MODULATORIOS INHIBITORIOS A PARCIALES, A TOTALMENTE ESTIMULANTES SOBRE LA POLIAMINA O UN EMPLAZAMIENTO MODULATORIO ESTRECHAMENTE RELACIONADO.
ES93923173T 1992-09-28 1993-09-28 Moduladores alostericos del receptor nmda. Expired - Lifetime ES2188596T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95281892A 1992-09-28 1992-09-28

Publications (1)

Publication Number Publication Date
ES2188596T3 true ES2188596T3 (es) 2003-07-01

Family

ID=25493263

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93923173T Expired - Lifetime ES2188596T3 (es) 1992-09-28 1993-09-28 Moduladores alostericos del receptor nmda.

Country Status (8)

Country Link
US (1) US5830998A (es)
EP (1) EP0625988B1 (es)
JP (1) JPH07505908A (es)
AU (1) AU680448B2 (es)
CA (1) CA2124566A1 (es)
DE (1) DE69332605T2 (es)
ES (1) ES2188596T3 (es)
WO (1) WO1994007914A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
CA2261568A1 (en) 1996-07-22 1998-01-29 University Of Utah Research Foundation Conantokins
WO1998003189A1 (en) * 1996-07-22 1998-01-29 Cognetix, Inc. Use of conantokins
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US5844077A (en) * 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
US6624288B1 (en) * 1997-12-16 2003-09-23 Cognetix, Inc. Gamma-conopeptides
EP1057023A1 (en) * 1998-02-10 2000-12-06 University of Utah Research Foundation Methods for purifying and assaying a conus v-carboxylase
EP1214335A4 (en) * 1999-09-10 2003-04-23 Univ Utah Res Found GAMMA-CARBOXYGLUTAMATE CONTAINING CONOPEPTIDES
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
WO2002026248A1 (en) * 2000-09-29 2002-04-04 Cognetix, Inc. Stable peptide formulations
US20030065138A1 (en) * 2001-03-07 2003-04-03 University Of Utah Research Foundation Linear gamma-carboxyglutamate rich conotoxins
EP1427404A4 (en) * 2001-08-20 2005-10-26 Maiken Nedergaard TREATMENT OF GLIAL TUMORS WITH GLUTAMATE ANTAGONISTS
EP1298581A1 (fr) * 2001-09-27 2003-04-02 C.S.E.M. Centre Suisse D'electronique Et De Microtechnique Sa Procédé et dispositif pour calculer les valeurs des neurones d'un réseau neuronal
JP2006514914A (ja) * 2002-02-14 2006-05-18 バイエル・フアーマシユーチカルズ・コーポレーシヨン 有機溶媒中および乾燥状態のペプチドの安定化における製剤の戦略
EP2397126B1 (en) 2009-02-12 2014-11-19 SNU R & DB Foundation Pharmaceutical composition containing glur2-lacking ampar antagonist for preventing or treating psychiatric illnesses
CN102167730A (zh) * 2011-01-29 2011-08-31 浙江大学 芋螺毒素类似物Glu-Con-G[1-13]、设计合成方法及用途
US10689418B2 (en) * 2015-12-22 2020-06-23 Universidad Nacional De Colombia Synthetic peptides that modulate the NMDA receptor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1417736A (fr) * 1963-12-17 1965-11-12 Asahi Chemical Ind Procédé pour réaliser la synthèse de l'alpha-aminoglutaronitrile, de l'acide dl-glutamique, et de leurs dérivés alcoylés
US3658968A (en) * 1970-06-11 1972-04-25 Merck & Co Inc Composition and method of treatment
US3769424A (en) * 1970-10-01 1973-10-30 Merck & Co Inc Composition and method of treating dopamine deficiency in brain tissue
US5051413A (en) * 1986-02-13 1991-09-24 Ciba-Geigy Corporation Unsaturated amino acids
US5175344A (en) * 1986-02-13 1992-12-29 Ciba-Geigy Corporation Unsaturated amino acids
ES2038690T3 (es) * 1986-02-13 1993-08-01 Ciba-Geigy Ag Aminoacidos insaturados.
US4806543A (en) * 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
CA1305177C (en) * 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
US5242947A (en) * 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
JP2757960B2 (ja) * 1988-10-17 1998-05-25 サントリー株式会社 （２Ｒ，３Ｓ，４Ｓ）−α−（カルボキシシクロプロピル）グリシン
US5049555A (en) * 1988-12-19 1991-09-17 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid receptors as neuroprotectants and anxiolytics
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
JP2780115B2 (ja) * 1989-07-24 1998-07-30 旭化成工業株式会社 虚血性脳細胞障害に対する細胞保護剤
US6017957A (en) * 1989-08-08 2000-01-25 The United States Of America As Represented By The Department Of Health And Human Services Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents
WO1991002523A1 (en) * 1989-08-17 1991-03-07 The Children's Medical Center Corporation Glutamatergic amino acid agonists and antagonists
US5189020A (en) * 1989-11-22 1993-02-23 Neurex Corporation Method of reducing neuronal damage using omega conotoxin peptides
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
DK101290D0 (da) * 1990-04-24 1990-04-24 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
GB9109007D0 (en) * 1991-04-26 1991-06-12 Merck Sharp & Dohme Therapeutic method
EP0518818A3 (en) * 1991-06-11 1993-04-28 Ciba-Geigy Ag Arylethers, their manufacture and use as medicament
DE69224069T2 (de) * 1991-09-09 1998-07-02 Warner-Lambert Co., Ann Arbor, Mich. Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
AU3074592A (en) * 1991-11-12 1993-06-15 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage

Also Published As

Publication number Publication date
EP0625988A1 (en) 1994-11-30
EP0625988A4 (en) 1998-03-04
EP0625988B1 (en) 2003-01-02
CA2124566A1 (en) 1994-04-14
US5830998A (en) 1998-11-03
DE69332605T2 (de) 2003-05-08
AU5294593A (en) 1994-04-26
JPH07505908A (ja) 1995-06-29
AU680448B2 (en) 1997-07-31
DE69332605D1 (de) 2003-02-06
WO1994007914A1 (en) 1994-04-14

Similar Documents

Publication Publication Date Title
ES2188596T3 (es) Moduladores alostericos del receptor nmda.
ES2173868T3 (es) Utilizacion de relaxina para la fabricacion de un medicamento destinado al tratamiento de enfermedades cardiovasculares.
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
NO20013727L (no) Anvendelse av Botulinumtoksin B for fremstilling av et medikament
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
ES2164111T3 (es) Empleo del principio activo flupirtina para la preparacion de un medicamento para combatir espasmos musculares.
ES2062943B1 (es) Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas.
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
DK505584A (da) Administrationssaet og farmaceutiske praeparater til anvendelse dertil
GB9212308D0 (en) Therapeutic compositions
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
NO153530C (no) Analogifremgangsm¨te for fremstilling av terapeutisk aktiv e substituerte heterocykliske benzamider.
FI973023A0 (fi) Liikakasvusairauksien yhdistetty terapeuttinen hoito
NO975140D0 (no) Transdermalt terapeutisk system (TTS) for administrasjon av testosteron
FR2399429A1 (fr) Composes tetrahydro-isoquinoleiniques myorelaxants (agents de blocage de la plaque neuro-musculaire) et medicament contenant ces substances
MX9300406A (es) Derivados azabiciclicos procedimientos para su preparacion y composiciones que los contienen.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
MX9307048A (es) Derivados de piridazinoquinazolona, y composicion farmaceutica que los contiene.
DK0703781T3 (da) Anvendelse af Efaroxan og derivater deraf til fremstilling af et lægemiddel til behandling af Parkinsons sygdom
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
ES2179166T3 (es) Composiciones para la prevencion y tratamiento de trastornos urogenitales, que contienen bismuto y uno o mas agentes antimicrobianos.
GR3032531T3 (en) Use of efaxoran and its derivatives for the production of drugs for treating neurodegenerative diseases
MX9204010A (es) Composicion farmaceutica que contiene 3(3-piridil)-1h,3-pirrol[1,2- c]tiazol-7-carboxamida y procedimiento para su preparacion.
MX9307679A (es) Derivados de furanona utiles en terapia.
DK0659079T3 (da) Transdermalt terapeutisk system med pentylentetrazol som aktivt stof.